Beilu Pharmaceutical
Beilu Pharmaceutical Co., Ltd., also known as Beilu Pharma, is a public Chinese drug company founded in 1992 and based in Beijing. It trades on the Shenzhen Stock Exchange under the ticker 300016 (ChiNext) after previously being listed on NEEQ; UBS helped with its 2009 listing. The company serves China and other markets such as Pakistan and Peru, and its products include Jiuwei Zhenxin Granules, gadopentetate dimeglumine injections, and Iohexol injections.
Beilu was financed by Infotech in 2008 and qualified to list on Shenzhen’s second board in May 2009, then joined ChiNext in October 2009. In 2014, it invested 30 million yuan in Geneseeq Technology, and in May 2016 it set up an industry buyout fund worth 610 million yuan. In June 2016 it increased its investment in Geneseeq. The company’s net profit exceeded 118 million yuan in 2017, and in 2020 it raised about 70.42 million dollars.
Website: beilupharma.com
This page was last edited on 2 February 2026, at 04:24 (CET).